A study of a several doses of a novel treatment for chronic itch compared to placebo for patients whose condition has not responded to other treatments
The sensation of itch is transmitted to the brain through the nervous system Several chemicals are involved in transmitting this signal This trial of VPD 737 is intended to treat this condition by blocking one of the chemicals involved in the transmission of the itch signal This is an oral drug administered once daily It has been used in other trials and has shown to be safe at the doses used in this trial The trial will involve once daily pills for 6 weeks. Subject will be asked to fill out questionnaires both electronically and on paper during the study period Patients will also be monitored for safety and will have blood taken for testing and several points during the trial Overall participation will last about 12 weeks
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
257
Center for Dermatology Clinical Research, Inc.
Visual Analog Scale
Time frame: 6 weeks
Verbal Response Scale
Time frame: 6 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Fremont, California, United States
Torrance Clinical Research Institute Inc.
Lomita, California, United States
Stanford University, Medical Dermatology
Redwood City, California, United States
UCSD Dermatology
San Diego, California, United States
The Center for Clinical and Cosmetic Research
Aventura, Florida, United States
Dermatology of Boca
Boca Raton, Florida, United States
Skin Care Research
Boca Raton, Florida, United States
Olympian Clinical Research
Tampa, Florida, United States
Advanced Medical Research, Inc.
Atlanta, Georgia, United States
Shideler Clinical Research Center
Carmel, Indiana, United States
...and 15 more locations